NU675 Unit 7 Pediatric Risperidone Metabolic Brief Example

Reviewed by Elspeth Marlowe, MSN, RN PMHNP Diagnosis and Management Across the Lifespan II Purdue University Global Free custom sample in 24 to 48h

This NU675 Unit 7 sample is a metabolic monitoring brief for a composite 13-year-old boy with autism whose outbursts have calmed over four years of risperidone while his BMI has climbed from the 62nd to the 96th percentile. It was prepared for Purdue Global NU 675, PMHNP Diagnosis and Management Across the Lifespan II, for the MSN's psychiatric mental health nurse practitioner track. It sets aside stopping a drug his family credits with restoring home life and fixes six measures with their schedules, drawing on the RUPP trial, the Correll cohort and the 2004 consensus. It pairs each abnormal result with an action, including metformin under the Anagnostou trial.

CourseNU675 PMHNP Diagnosis and Management Across the Lifespan II
UnitUnit 7
Paper typeMetabolic monitoring brief
LengthAbout 540 words, 4 pages double-spaced
FormatAPA 7 student paper
SchoolPurdue University Global
ProgramMSN
UpdatedSeptember 2026

Free sample paper for NU675 Unit 7

1

The 62nd Percentile to the 96th: A Metabolic Monitoring Brief for a 13-Year-Old With Autism Four Years Into Risperidone

[Student Name]

Purdue University Global

NU675: PMHNP Diagnosis and Management Across the Lifespan II

Unit 7 Metabolic Monitoring Brief

[Instructor Name]

[Date]

The patient is composite; values and dates are bracketed.

What this part is doingThe brief states what it will not decide, stopping the drug, so it can focus on what monitoring can change.
2

Why Monitoring, Not Stopping

[Jayden], [13], has autism spectrum disorder and began risperidone at [nine] for severe tantrums, aggression and self-injury. His parents describe the change as "getting our family back." Risperidone has randomized trial support for these problems in children with autism; in the landmark trial it reduced serious behavioral problems compared with placebo and was associated with weight gain (McCracken et al., 2002). His family and his school do not want to stop it, and a trial off medication may be considered later. The immediate task is to measure and respond to its metabolic effects.

Children and adolescents appear especially vulnerable. In a cohort of youth starting second-generation antipsychotics for the first time, all the drugs studied were associated with significant weight gain within about three months, and risperidone was associated with a significant rise in triglycerides (Correll et al., 2009). At the 96th percentile, Jayden has crossed into obesity, and the question is no longer whether to monitor but what each result will change.

What Gets Measured and When

1. Weight, height and BMI percentile: every visit, at least every [three] months, plotted on a growth chart.

2. Waist circumference: every [six] months.

3. Blood pressure, compared with age and height percentiles: every visit.

4. Fasting glucose or A1c and a fasting lipid panel: now, then every [six] months while BMI stays above the 95th percentile, and at least yearly otherwise, more often than the adult consensus schedule because of his age and the rise already seen (American Diabetes Association et al., 2004).

5. Liver enzymes: now, then yearly, since obesity in adolescence raises the risk of fatty liver.

6. Prolactin: only if symptoms such as breast enlargement appear.

Which Result Triggers Which Action

1. BMI rising by more than [five] percentile points over six months: a meeting with a dietitian and a family activity plan.

2. BMI above the 95th percentile despite lifestyle measures for [three] months: discuss metformin. In a randomized trial in young people with autism who had gained weight on atypical antipsychotics, metformin reduced BMI z-scores more than placebo over sixteen weeks, with more gastrointestinal side effects (Anagnostou et al., 2016).

3. Fasting glucose of [100] mg/dL or more, or an A1c of [5.7] percent or more: repeat within [three] months and refer to pediatric endocrinology if confirmed.

4. Triglycerides above [150] mg/dL or LDL above [130] mg/dL: dietary review and repeat in [three] months.

5. Blood pressure at or above the 95th percentile on three visits: pediatric review.

6. Any two of the above: revisit whether a lower dose, or a trial of a different medication with less metabolic effect, is warranted.

What this part is doingEach monitored value is paired with the action it triggers, which is what turns a schedule into a plan.
3

Who Does What

The clinic orders and reviews the tests. His parents keep a copy of the growth chart and the thresholds. His school nurse has agreed to support the activity plan in physical education. Results are reviewed with the family at each visit, using the chart they can see.

What this part is doingGiving the family the chart and the thresholds makes them partners in monitoring rather than recipients of results.
4

References

American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, & North American Association for the Study of Obesity. (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care, 27(2), 596-601. https://doi.org/10.2337/diacare.27.2.596

Anagnostou, E., Aman, M. G., Handen, B. L., Sanders, K. B., Shui, A., Hollway, J. A., Brian, J., Arnold, L. E., Capano, L., Hellings, J. A., Butter, E., Mankad, D., Tumuluru, R., Kettel, J., Newsom, C. R., Hadjiyannakis, S., Peleg, N., Odrobina, D., McAuliffe-Bellin, S., . . . Veenstra-VanderWeele, J. (2016). Metformin for treatment of overweight induced by atypical antipsychotic medication in young people with autism spectrum disorder: A randomized clinical trial. JAMA Psychiatry, 73(9), 928-937. https://doi.org/10.1001/jamapsychiatry.2016.1232

Correll, C. U., Manu, P., Olshanskiy, V., Napolitano, B., Kane, J. M., & Malhotra, A. K. (2009). Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA, 302(16), 1765-1773. https://doi.org/10.1001/jama.2009.1549

McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., Arnold, L. E., Lindsay, R., Nash, P., Hollway, J., McDougle, C. J., Posey, D., Swiezy, N., Kohn, A., Scahill, L., Martin, A., Koenig, K., Volkmar, F., Carroll, D., . . . McMahon, D. (2002). Risperidone in children with autism and serious behavioral problems. New England Journal of Medicine, 347(5), 314-321. https://doi.org/10.1056/NEJMoa013171

NU675 Unit 7 instructions, in plain terms

The Unit 7 brief asks you to set up monitoring for the adverse effects of a psychotropic medication in a specific patient. Prompts usually want the reason the medication is continued, the risks that need monitoring and their evidence, what will be measured and how often, what result will trigger what action, and who is responsible for each step. Briefs of two to three pages are common. Faculty reward monitoring schedules adapted to the patient's age and current results rather than copied from adult guidance, and briefs that link every measure to a decision. Including the family's role, and the thresholds they can watch themselves, makes the plan more likely to be followed between visits.

How the NU 675 Unit 7 example is put together

The brief opens by explaining why risperidone continues, citing the RUPP trial, and then describes the metabolic vulnerability of young people with the Correll cohort, with a highlighted sentence on his crossing into obesity. Six measures follow with their schedules, adapted from the 2004 consensus to his age and rising values. A separate list pairs six results with six actions, from a dietitian referral to discussing metformin, with the Anagnostou trial results, and finally a review of dose or drug if two thresholds are crossed. A last section divides responsibility among the clinic, his parents and the school nurse, and a margin note explains why the family keeps the chart.

Reading the NU675 Unit 7 grading rubric

Monitoring briefs are generally graded on the rationale for continuing treatment, the fit of the schedule to the patient, the link between results and actions, the evidence cited and the division of responsibility. The rationale row earns full points when the benefit is stated along with the risk. Schedule fit rewards adaptation to a child's growth charts and current values. The link row is where many briefs lose marks, because they list tests without saying what any result would change. Evidence points go to pediatric data where they exist. Responsibility credit depends on naming who orders, who reviews and what the family and school do between visits.

NU675 Unit 7 help: mistakes that cost points

The most common error is applying adult cutoffs to a child, whose weight and blood pressure must be read against growth percentiles. Another is listing tests without actions, which makes monitoring a ritual. Students often recommend stopping the medication without weighing what the family would lose. Some briefs forget liver enzymes in an adolescent with obesity. Others mention metformin without its evidence or its side effects. And a brief that leaves the family out of the plan misses the people best placed to notice weight change, activity and eating patterns between clinic visits, which is where most of the change happens. Plot every value on the chart the family can see.

Get an NU675 Unit 7 example written to your instructions

Give the agent, how many years the patient has taken it and whatever values your NU675 Unit 7 case lists; duration shapes a long-term brief as much as the drug does. Add the rubric, and a free first custom brief follows within 24-48h, with age-appropriate thresholds, an action beside every measure and the trajectory read first. The paper above is an original model document written by our desk, not a submitted student paper and not an official Purdue University Global document.

Request this unit free All NU675 units Finished samples

More NU675 papers and MSN samples

NU675 Unit 7 questions, answered

How does metabolic monitoring differ for children and adolescents?

Thresholds come from growth charts rather than adult cutoffs, because a growing child's weight and blood pressure are judged against age and sex norms. Young people also tend to gain weight faster on antipsychotics than adults. Say which pediatric references you use, report percentiles or z-scores, and explain how you separate expected growth from drug-related gain.

Should the brief recommend switching to a lower-risk antipsychotic?

It can raise the option, with its trade-offs. A switch may lower metabolic risk but could cost behavioral gains that took years to achieve, so the family's view matters. Present it as one action among several, tied to a threshold, and leave the decision to the prescriber and family, with the reasoning written out.

What if the case gives only some of the monitoring values?

List every measure the brief requires, report the values supplied, and mark the missing ones as needed at the next visit, with a reason for each. Do not invent numbers. A brief that identifies gaps in past monitoring can be stronger than one with a complete table, because it shows the author checked what had actually been done.

Where can I find a free NU675 Unit 7 sample paper?

The complete NU675 Unit 7 metabolic monitoring brief is on this page, with the reasons for continuing risperidone, six measures and schedules, six results paired with actions and a division of responsibility, plus four references. A brief for your own patient can be drafted.

When is metformin considered in NU675 Unit 7?

If his BMI stays above the 95th percentile after three months of lifestyle measures. In a randomized trial in young people with autism who had gained weight on atypical antipsychotics, metformin reduced BMI z-scores more than placebo over sixteen weeks.